Dr. Atkins Discusses the Adjuvant Treatment of Melanoma

Michael B. Atkins, MD
Published: Thursday, Dec 07, 2017



Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the adjuvant treatment of melanoma.

For the past 20 years, there have been constant debate over what adjuvant treatments should be used in which patients with melanoma, says Atkins. But none of the available treatments were effective of tolerable enough to justify their widespread use, Atkins add.

Recently, a trial looking at vemurafenib (Zelboraf), the COMBI-d study of dabrafenib (Tafinlar) plus trametinib (Mekinist), and a trial comparing nivolumab (Opdivo) with high-dose ipilimumab (Yervoy), showed promise across varying stages of disease.
 
SELECTED
LANGUAGE


Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the adjuvant treatment of melanoma.

For the past 20 years, there have been constant debate over what adjuvant treatments should be used in which patients with melanoma, says Atkins. But none of the available treatments were effective of tolerable enough to justify their widespread use, Atkins add.

Recently, a trial looking at vemurafenib (Zelboraf), the COMBI-d study of dabrafenib (Tafinlar) plus trametinib (Mekinist), and a trial comparing nivolumab (Opdivo) with high-dose ipilimumab (Yervoy), showed promise across varying stages of disease.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x